Location of Repository

BRAFV600E mutations in malignant melanoma are associated with increased expressions of BAALC

By David Schrama, Gunhild Keller, Roland Houben, Christian G Ziegler, Claudia S Vetter-Kauczok, Selma Ugurel and Jürgen C Becker
Topics: Short Paper
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2483271
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (2003). Aaronson SA: BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res
    2. (2007). Allada R: Meta-analysis of Drosophila circadian microarray studies identifies a novel set of rhythmically expressed genes. PLoS Comput Biol
    3. (2002). BL: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res
    4. (2003). CD: BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a cancer and leukemia group B study. Blood
    5. (2007). Confirmation of a BRAF mutation-associated gene expression signature in melanoma. Pigment Cell Res
    6. (2007). D: B-RAF and N-RAS mutations are preserved during short time In Vitro propagation and differentially impact prognosis. PLoS ONE
    7. (2005). de la CA: Baalc, a marker of mesoderm and muscle. Gene Expr Patterns
    8. (2003). de la CA: BAALC, a novel marker of human hematopoietic progenitor cells. Exp Hematol
    9. (2001). de la CA: BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proc Natl Acad Sci USA
    10. (2005). Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis
    11. (2002). Futreal PA: Mutations of the BRAF gene in human cancer.
    12. (2006). G r a f N , E i l e r s M , G e s s l e r M : Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters.
    13. (2003). Gene expression phenotypic models that predict the activity of oncogenic pathways.
    14. (2004). Genetic progression of metastatic melanoma. Cancer Lett
    15. (2004). Hemminki K: BRAF mutations are common somatic events in melanocytic nevi.
    16. (2004). Marais R: V599EB-RAF is an oncogene in melanocytes. Cancer Res
    17. (2007). Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Res
    18. (2004). NK: Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene
    19. (2005). Peeper DS: BRAFE600-associated senescence-like cell cycle arrest of human naevi.
    20. (2006). S: Combining multiple microarrays in the presence of controlling variables. Bioinformatics
    21. (2006). Shirsat NV: Induction of BAALC and down regulation of RAMP3 in astrocytes treated with differentiation inducers. Cell Biol Int
    22. (2006). SL: Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol
    23. (2004). UR: Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.